Uploaded August 2026 | Updated September 2026, 3 weeks ago
Sponsor: FlexBeam
FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.
Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.
Link: rechargehealthas.sjv.io/jRQyQ5
----------
In this week's Longevity News Roundup, Phil Newman explores whether aging research has overlooked half the population, why supplement quality is becoming a scientific issue, how NAD+ science is moving into pharmaceutical development, and what superagers reveal about the limits of genetic prediction.
- A new $7.5 million NIH-funded center at USC will investigate sex differences in aging after decades of male-biased research. The initiative could reshape biomarkers, clinical trials, and personalized longevity interventions.
- Swiss longevity company Timeline won a $5.3 million judgment against sellers falsely marketing products as containing urolithin A. The ruling reinforces that scientific evidence depends on products containing the same ingredient and dose used in clinical research.
- Niagen Bioscience has partnered with Evotec to advance NB4168, an oral NAD+ small molecule for a rare pediatric neurodegenerative disease. The collaboration highlights how longevity companies are increasingly translating supplement science into regulated drug development.
- Researchers found that superagers shared similar Alzheimer's genetic risk profiles with cognitively average older adults. Rather than supporting a DNA destiny narrative, the findings point toward resilience mechanisms that future studies will explore through biomarkers, immune profiling, brain imaging, and lifestyle.
----------
News & References:
- What if aging research has been studying the wrong sex? → https://longevity.technology/news/what-if-aging-research-has-been-studying-the-wrong-sex/
- Timeline wins $5.3m in fake urolithin A case → https://longevity.technology/news/timeline-wins-5-3m-in-fake-urolithin-a-case/
- Niagen Bioscience teams up with Evotec to prepare rare disease drug for human trials → https://longevity.technology/news/niagen-bioscience-teams-up-with-evotec-to-prepare-rare-disease-drug-for-human-trials/
- SuperAgers challenge the DNA destiny narrative → https://longevity.technology/news/superagers-challenge-the-dna-destiny-narrative/
----------
Hosts:
Phil Newman: qrco.de/bgXpNY
Sponsor: FlexBeam
FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.
Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.
Link: rechargehealthas.sjv.io/jRQyQ5
----------
In this week's Longevity News Roundup, Phil Newman explores whether aging research has overlooked half the population, why supplement quality is becoming a scientific issue, how NAD+ science is moving into pharmaceutical development, and what superagers reveal about the limits of genetic prediction.
- A new $7.5 million NIH-funded center at USC will investigate sex differences in aging after decades of male-biased research. The initiative could reshape biomarkers, clinical trials, and personalized longevity interventions.
- Swiss longevity company Timeline won a $5.3 million judgment against sellers falsely marketing products as containing urolithin A. The ruling reinforces that scientific evidence depends on products containing the same ingredient and dose used in clinical research.
- Niagen Bioscience has partnered with Evotec to advance NB4168, an oral NAD+ small molecule for a rare pediatric neurodegenerative disease. The collaboration highlights how longevity companies are increasingly translating supplement science into regulated drug development.
- Researchers found that superagers shared similar Alzheimer's genetic risk profiles with cognitively average older adults. Rather than supporting a DNA destiny narrative, the findings point toward resilience mechanisms that future studies will explore through biomarkers, immune profiling, brain imaging, and lifestyle.
----------
News & References:
- What if aging research has been studying the wrong sex? → https://longevity.technology/news/what-if-aging-research-has-been-studying-the-wrong-sex/
- Timeline wins $5.3m in fake urolithin A case → https://longevity.technology/news/timeline-wins-5-3m-in-fake-urolithin-a-case/
- Niagen Bioscience teams up with Evotec to prepare rare disease drug for human trials → https://longevity.technology/news/niagen-bioscience-teams-up-with-evotec-to-prepare-rare-disease-drug-for-human-trials/
- SuperAgers challenge the DNA destiny narrative → https://longevity.technology/news/superagers-challenge-the-dna-destiny-narrative/
----------
Hosts:
Phil Newman: qrco.de/bgXpNY
